News for Spring Bank Pharmaceuticals Inc (SBPH)

F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today... | November 10, 2021

Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) --  F-star...

F-star Therapeutics Inc. (FSTX), a clinical-stage biopharmaceutical company developing next generation bispecific immunotherapies, has a couple of catalysts to watch in the coming months.

Company to Host Conference Call Today at 9 a.m. EDT...

Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination with Atezolizumab...

In an all-Cambridge deal, F-star Therapeutics has lined up a huge payback from a licensing agreement with AstraZeneca. AstraZeneca will receive global rights to research, develop and commercialise next generation Stimulator of Interferon Genes (STING) inhibitor compounds from F-star. F-star is now eligible to receive upfront and near-term payments of up to $12 million. It will